% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Schroeder:299587,
      author       = {T. Schroeder and S. Flossdorf and C. Schuh and C. Pabst and
                      M. Stadler and J. Schetelig and C. Wehr and M. Stelljes and
                      E. Sala and A. Burchert and J. Winkler and H. C. Reinhardt
                      and N. Kröger and K. Fleischhauer$^*$ and C. Rautenberg},
      title        = {{O}utcome of {P}atients with {IDH}-mutated {AML} following
                      {A}llogeneic {S}tem {C}ell {T}ransplantation - a
                      {R}etrospective {A}nalysis on behalf of the {G}erman
                      {R}egistry for {H}ematopoietic {S}tem {C}ell
                      {T}ransplantation and {C}ell {T}herapy, {DRST}.},
      journal      = {Transplantation and cellular therapy},
      volume       = {31},
      number       = {5},
      issn         = {2666-6375},
      address      = {[Amsterdam]},
      publisher    = {Elsevier B. V.},
      reportid     = {DKFZ-2025-00528},
      pages        = {303.e1-303.e9},
      year         = {2025},
      note         = {Volume 31, Issue 5, May 2025, Pages 303.e1-303.e9},
      abstract     = {Mutations in isocitrate dehydrogenase 1 and 2 genes (IDH1
                      and IDH2) are found in $15\%$ to $20\%$ of patients with
                      acute myeloid leukemia (AML). IDH inhibitors have been
                      introduced as targeted treatment and are currently under
                      investigation as maintenance therapy after allogeneic
                      transplantation (allo-SCT). Since reports about the outcome
                      of IDH1- and IDH2-mutated (IDHmut) AML after allo-SCT are
                      limited, we retrospectively analyzed 356 IDH-mutated AML
                      patients (IDH1 $40\%,$ IDH2 $60\%).$ Ten patients $(4\%)$
                      had received an IDH inhibitor prior transplantation, but
                      none had received maintenance with IDH inhibitors. After a
                      median follow-up of 24 months 3-year probabilities of
                      overall (OS) and event-free (EFS) survival, relapse and
                      non-relapse mortality (NRM) for the entire cohort were
                      $73\%,$ $60\%,$ $27\%$ and $13\%$ respectively. While 3-year
                      OS $(78\%$ vs $70\%),$ EFS $(56\%$ vs. $63\%)$ and NRM
                      $(10\%$ vs $14\%)$ rates were similar for IDH1mut and
                      IDH2mut patients, relapse incidence was numerically higher
                      in IDH1mut patients $(34\%$ vs. $24\%)$ and landmark
                      analysis suggested a continuous rise of relapse incidence
                      preferentially in IDH1mut AML also beyond the first year.
                      Concordantly, IDH2 mutation was associated with superior EFS
                      and by trend with lower relapse incidence. The strongest
                      risk factor for adverse outcomes, however, was AML not in
                      CR. This analysis provides benchmarks for interpretation of
                      results emerging from post-transplant maintenance trials in
                      IDHmut AML and suggest that maintenance strategies may
                      further optimize the promising outcome in this molecularly
                      defined subgroup by reducing relapse risk, especially for
                      patients whose AML is not in remission at time of alloHCT.},
      keywords     = {AML (Other) / IDH mutation (Other) / allogeneic
                      transplantation (Other) / maintenance (Other) / relapse
                      (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40058648},
      doi          = {10.1016/j.jtct.2025.02.018},
      url          = {https://inrepo02.dkfz.de/record/299587},
}